Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.19 USD
-0.03 (-2.46%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.17 -0.02 (-1.68%) 5:50 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Lexicon Pharmaceuticals, Inc. has a market cap of $443.35M, which represents its share price of $1.22 multiplied by its outstanding shares number of 363.40M. As a small-cap company, LXRX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
LXRX 1.19 -0.03(-2.46%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
Other News for LXRX
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution
Is LXRX likely to continue higher? Crossed Above 20 Day Moving Average shows up after rocketing 11.93%
MACD Bearish Centerline Cross appears for LXRX after 0.91% move
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
20 Day Moving Average Resistance appears for LXRX after 1.79% move